{"id":1760,"date":"2015-11-26T09:58:15","date_gmt":"2015-11-26T08:58:15","guid":{"rendered":"http:\/\/semmelweis.hu\/nki\/?p=1760"},"modified":"2015-11-26T10:00:35","modified_gmt":"2015-11-26T09:00:35","slug":"semmelweises-eloado-az-oxford-masterclass-2015-os-ibd-tovabbkepzesen","status":"publish","type":"post","link":"https:\/\/semmelweis.hu\/nki\/en\/2015\/11\/26\/semmelweises-eloado-az-oxford-masterclass-2015-os-ibd-tovabbkepzesen\/","title":{"rendered":"Semmelweises el\u0151ad\u00f3 az Oxford MasterClass 2015-\u00f6s IBD tov\u00e1bbk\u00e9pz\u00e9s\u00e9n"},"content":{"rendered":"<p><a href=\"https:\/\/semmelweis.hu\/nki\/files\/2015\/11\/Oxford-Gecse-K-230x300.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-medium wp-image-1761\" src=\"https:\/\/semmelweis.hu\/nki\/files\/2015\/11\/Oxford-Gecse-K-230x300-230x300.jpg\" alt=\"Oxford-Gecse-K-230x300\" width=\"230\" height=\"300\" \/><\/a>Egyed\u00fcl\u00e1ll\u00f3 magyar kutat\u00e1sr\u00f3l sz\u00e1molt be Dr. Gecse Krisztina, az I. Sz. Belgy\u00f3gy\u00e1szati Klinika tan\u00e1rseg\u00e9dje, aki egyed\u00fcli nem nyugat-eur\u00f3pai vagy amerikai r\u00e9szvev\u0151k\u00e9nt kapott megh\u00edv\u00e1st az Oxford MasterClass 2015-\u00f6s IBD (inflammatory bowel disease, gyullad\u00e1sos b\u00e9lbetegs\u00e9gek) tov\u00e1bbk\u00e9pz\u00e9s\u00e9re. Biosimilars: first or last? c\u00edm\u0171 el\u0151ad\u00e1s\u00e1ban egy olyan vizsg\u00e1lat eredm\u00e9nyeit mutatta be, amely a magyarorsz\u00e1gi biol\u00f3giai centrumok kooper\u00e1ci\u00f3jak\u00e9nt j\u00f6tt l\u00e9tre \u00e9s a biohasonl\u00f3 infliximab hat\u00e9konys\u00e1g\u00e1t vizsg\u00e1lta gyullad\u00e1sos b\u00e9lbetegs\u00e9gekben. \u00a0Az adatokb\u00f3l az der\u00fclt ki, hogy ezek a gy\u00f3gyszerek hat\u00e9konyan \u00e9s biztons\u00e1ggal alkalmazhat\u00f3k gyullad\u00e1sos b\u00e9lbetegs\u00e9gekben.<\/p>\n<p>Dr. Gecse Krisztin\u00e1t a tov\u00e1bbk\u00e9pz\u00e9sre az IBD Masterclass szervez\u0151je, Simon Travis professzor h\u00edvta meg. Magyarorsz\u00e1gon Eur\u00f3p\u00e1ban az els\u0151k k\u00f6z\u00f6tt kezdtek haszn\u00e1lni biohasonl\u00f3 infliximabot a gyullad\u00e1sos b\u00e9lbetegek ter\u00e1pi\u00e1j\u00e1ban \u2013 mondta el Dr. Gecse Krisztina. A biohasonl\u00f3k olyan biol\u00f3giai gy\u00f3gyszerek, amelyek az origin\u00e1lis referencia k\u00e9sz\u00edtm\u00e9ny szabadalmi v\u00e9detts\u00e9g\u00e9nek lej\u00e1rt\u00e1t k\u00f6vet\u0151en ker\u00fclnek forgalomba. Az I. Sz. Belgy\u00f3gy\u00e1szati Klinik\u00e1n prospekt\u00edv adatgy\u0171jt\u00e9sbe kezdtek egy multicentrikus vizsg\u00e1lat keret\u00e9ben, egy\u00fcttm\u0171k\u00f6dve orsz\u00e1gszerte tov\u00e1bbi 12 biol\u00f3giai ter\u00e1pi\u00e1s centrummal.<\/p>\n<p>A szakember hangs\u00falyozta, hogy a biohasonl\u00f3 infliximab IBD-ben t\u00f6rt\u00e9n\u0151 klinikai alkamaz\u00e1s\u00e1r\u00f3l a hat\u00e9konys\u00e1g \u00e9s a biztons\u00e1goss\u00e1g tekintet\u00e9ben ezid\u00e1ig csak korl\u00e1tozott, retrospekt\u00edv adatok \u00e1lltak rendelkez\u00e9sre. Az orsz\u00e1gos adatgy\u0171jt\u00e9sen alapul\u00f3, az el\u0151ad\u00e1s\u00e1ban ismertetett adatok azt mutatj\u00e1k, hogy a biohasonl\u00f3 infliximab hat\u00e9konyan \u00e9s biztons\u00e1goss\u00e1ggal alkalmazhat\u00f3 gyullad\u00e1sos b\u00e9lbetegs\u00e9gekben.<\/p>\n<p>Pogr\u00e1nyi P\u00e9ter<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p><a href=\"https:\/\/semmelweis.hu\/nki\/files\/2015\/11\/Oxford-Gecse-K-230x300.jpg\"><\/a> Egyed\u00fcl\u00e1ll\u00f3 magyar kutat\u00e1sr\u00f3l sz\u00e1molt be Dr. Gecse Krisztina, az I. Sz. Belgy\u00f3gy\u00e1szati Klinika tan\u00e1rseg\u00e9dje, aki egyed\u00fcli nem nyugat-eur\u00f3pai vagy amerikai r\u00e9szvev\u0151k\u00e9nt kapott megh\u00edv\u00e1st az Oxford MasterClass 2015-\u00f6s IBD (inflammatory bowel disease, gyullad\u00e1sos b\u00e9lbetegs\u00e9gek) tov\u00e1bbk\u00e9pz\u00e9s\u00e9re. Biosimilars: first or last? c\u00edm\u0171 el\u0151ad\u00e1s\u00e1ban egy olyan vizsg\u00e1lat eredm\u00e9nyeit mutatta be, amely a magyarorsz\u00e1gi biol\u00f3giai centrumok kooper\u00e1ci\u00f3jak\u00e9nt j\u00f6tt l\u00e9tre \u00e9s &hellip;<\/p>\n","protected":false},"author":362,"featured_media":1761,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[151],"tags":[],"class_list":["post-1760","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-hirek-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/nki\/wp-json\/wp\/v2\/posts\/1760","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/nki\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/semmelweis.hu\/nki\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/nki\/wp-json\/wp\/v2\/users\/362"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/nki\/wp-json\/wp\/v2\/comments?post=1760"}],"version-history":[{"count":1,"href":"https:\/\/semmelweis.hu\/nki\/wp-json\/wp\/v2\/posts\/1760\/revisions"}],"predecessor-version":[{"id":1762,"href":"https:\/\/semmelweis.hu\/nki\/wp-json\/wp\/v2\/posts\/1760\/revisions\/1762"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/nki\/wp-json\/wp\/v2\/media\/1761"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/nki\/wp-json\/wp\/v2\/media?parent=1760"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/nki\/wp-json\/wp\/v2\/categories?post=1760"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/nki\/wp-json\/wp\/v2\/tags?post=1760"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}